Drugs / SYH9056
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06771245 | Jan 2025 → Mar 2026 overdue | essential hypertension | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH9056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06771245 ↗ |
| Route | Oral | “PO once daily, 1 tablet each time” NCT06771245 ↗ |